Literature DB >> 16766051

Slow antagonist dissociation and long-lasting in vivo receptor protection.

Georges Vauquelin1, Isabelle Van Liefde.   

Abstract

The ability of antagonists to form slowly dissociating complexes with their cognate receptors has repeatedly been proposed to contribute to their long-lasting clinical actions. Yet specific conditions seem to be necessary for this to take place. The elimination rate of the free antagonist and the variation of agonist concentration with time have important roles. Slowly dissociating antagonists are likely to exert longer efficient receptor protection in vivo than are fast-dissociating antagonists when the half-life of the antagonist-receptor complex exceeds that of the free antagonist. However, when the half-life of the free antagonist prevails, longer effective protection by slowly dissociating antagonists occurs only if the receptor is exposed to rapid fluctuations in free agonist concentration.

Mesh:

Substances:

Year:  2006        PMID: 16766051     DOI: 10.1016/j.tips.2006.05.001

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  20 in total

1.  Functional efficacy of adenosine A₂A receptor agonists is positively correlated to their receptor residence time.

Authors:  Dong Guo; Thea Mulder-Krieger; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 2.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.

Authors:  A Packeu; M Wennerberg; A Balendran; G Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

4.  Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.

Authors:  Georges Vauquelin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-28       Impact factor: 3.000

5.  A high-affinity, high-stability photoacoustic agent for imaging gastrin-releasing peptide receptor in prostate cancer.

Authors:  Jelena Levi; Ataya Sathirachinda; Sanjiv S Gambhir
Journal:  Clin Cancer Res       Date:  2014-05-21       Impact factor: 12.531

6.  Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector.

Authors:  Wael R Abd-Elgaliel; Fabio Gallazzi; Jered C Garrison; Tammy L Rold; Gary L Sieckman; Said Daibes Figueroa; Timothy J Hoffman; Susan Z Lever
Journal:  Bioconjug Chem       Date:  2008-09-23       Impact factor: 4.774

7.  The implications of target saturation for the use of drug-target residence time.

Authors:  Wilhelmus E A de Witte; Meindert Danhof; Piet H van der Graaf; Elizabeth C M de Lange
Journal:  Nat Rev Drug Discov       Date:  2018-12-28       Impact factor: 84.694

Review 8.  Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.

Authors:  Eric P Zorrilla; Markus Heilig; Harriet de Wit; Yavin Shaham
Journal:  Drug Alcohol Depend       Date:  2013-01-05       Impact factor: 4.492

9.  Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.

Authors:  Luis Almeida; José Francisco Rocha; Amílcar Falcão; P Nuno Palma; Ana I Loureiro; Roberto Pinto; Maria João Bonifácio; Lyndon C Wright; Teresa Nunes; Patrício Soares-da-Silva
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

10.  Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.

Authors:  José Francisco Rocha; Luis Almeida; Amílcar Falcão; P Nuno Palma; Ana I Loureiro; Roberto Pinto; Maria João Bonifácio; Lyndon C Wright; Teresa Nunes; Patrício Soares-da-Silva
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.